RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Plasmacytoma: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Adenopathy and Extensive Skin Patch Overlying a Plasmacytoma (AESOP) Syndrome Associated With a Solitary Bone Plasmacytoma of the Left Scapula: A Rare Paraneoplastic Presentation Managed With High-Precision Radiotherapy
Prakash A et al. (16 October 2026)
https://europepmc.org/search?query=Adenopathy%20and%20Extensive%20Skin%20Patch%20Overlying%20a%20Pl
- 2.
Isolated Endobronchial Plasmacytoma in a Patient With Rheumatoid Arthritis Taking Methotrexate.
Wang Shuyun et al., The Journal of rheumatology (15 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42880890/
- 3.
Extramedullary plasmacytoma or plasmablastic lymphoma? On the role of Ki-67 in the assessment of light chain restriction.
Teco Cortes J A, Revista de gastroenterologia de Mexico (English) (14 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42875339/
- 4.
Diagnostic challenges posed by the wide morphological and immunophenotypic spectrum of plasma cell neoplasms.
Chuang Shih-Sung et al., Blood research (2 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42826002/
- 5.
RADIOGRAPHIC ANALYSIS OF PLASMABLASTIC LYMPHOMA AND MULTIPLE MYELOMA/PLASMACYTOMA IN THE JAWS: A COMPARATIVE APPROACH
Nathália Rodrigues Gomes et al., Oral Surgery Oral Medicine Oral Pathology and Oral Radiology (1 October 2026)
https://doi.org/10.1016/j.oooo.2026.09.011
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Plasmacytoma
Plasmacytoma is a rare tumour made of abnormal plasma cells, a type of white blood cell that makes antibodies. It usually appears as a single growth, either in a bone or in soft tissue such as the upper airway. Radiotherapy is the main treatment, sometimes with surgery. Some people later develop multiple myeloma, so regular follow up is important.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Common Questions
What is Plasmacytoma?
Plasmacytoma is a rare tumour made of abnormal plasma cells, a type of white blood cell that makes antibodies. It usually appears as a single growth, either in a bone or in soft tissue such as the upper airway. Radiotherapy is the main treatment, sometimes with surgery. Some people later develop multiple myeloma, so regular follow up is important.
How many clinical trials are available for Plasmacytoma?
RareWays currently indexes 25 clinical trials for Plasmacytoma, of which 3 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Plasmacytoma come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Plasmacytoma.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.